

## **Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer (ID 7)**

<https://cslide.ctimeetingtech.com/breast24hybrid/attendee/confcal/show/session/7>

---

**Date** Thu, 16.05.2024

**Room** Frankfurt Hall

**Time** 12:45 - 13:45

**Chairs** Wolfgang Janni (Ulm, Germany)

**Session Description** [Click Here to Vote \(https://breast2024.cnf.io/sessions/gjww/#!/dashboard\)](https://breast2024.cnf.io/sessions/gjww/#!/dashboard)

### **Welcome and introduction (ID 93)**

**Lecture Time** 12:45 - 12:50

**Speakers** Wolfgang Janni (Ulm, Germany)

### **Unmet need in HR+/HER2- early breast cancer (ID 94)**

**Lecture Time** 12:50 - 12:55

**Speakers** Wolfgang Janni (Ulm, Germany)

### **Exploring CDK4/6 inhibitor clinical data in HR+/HER2- early breast cancer (ID 95)**

**Lecture Time** 12:55 - 13:15

**Speakers** Carlos H. Barrios (Porto Alegre, Brazil)

### **Reviewing the treatment landscape for HR+/HER2- advanced breast cancer (ID 96)**

**Lecture Time** 13:15 - 13:20

**Speakers** Wolfgang Janni (Ulm, Germany)

### **Analyzing first-line CDK4/6 inhibitor clinical data in HR+/HER2- advanced breast cancer (ID 97)**

**Lecture Time** 13:20 - 13:40

**Speakers** Stephanie L. Graff (Providence, United States of America)

### **Closing and key takeaways (ID 98)**

**Lecture Time** 13:40 - 13:45

**Speakers** Wolfgang Janni (Ulm, Germany)